Generic Name and Formulations:
Retapamulin 1%; oint.
Indications for ALTABAX:
Topical treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes in patients ≥9 months of age.
Adults and Children:
<9 months: not recommended. ≥9 months: apply thin layer to affected area (up to 100cm2 in total area in adults or 2% total body surface area in children) twice daily for 5 days. May cover with bandage or gauze dressing. Reevaluate if no improvement in symptoms within 3–4 days after starting treatment.
Not for intraoral, intranasal, ophthalmic, or intravaginal use. Discontinue if irritation or sensitization occurs. Prolonged use may result in superinfection. Pregnancy (Cat.B). Nursing mothers.
Application site irritation.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- Two Programs, One Goal: Meeting the Challenges of Oncology Navigation
- Navigating Patients with Hematologic Malignancies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|